Results 1 to 10 of about 3,460 (162)
Therapeutic Advances in Musculoskeletal Disease, 2022 Objectives: The Simplified Disease Activity Index (SDAI) is a recommended composite score for assessing the remission status in patients with rheumatoid arthritis (RA).
Gerd R Burmester +2 more
exaly +2 more sources
Научно-практическая ревматология, 2005 Objective. To assess significance of Simplified Disease Activity Index (SDAI) in early arthritis. Material and methods . 76 pts with suspicion of rheumatoid arthritis (RA), duration of the disease less than 6 months (3,6±1,7 months), meanage48,5±14years ...
N A ChemeriS, D E Karateev, E L Nassonov
doaj +2 more sources
What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis [PDF]
RMD Open, 2023 Objectives A treat-to-target (T2T) strategy has been shown to be superior to usual care in rheumatoid arthritis (RA), but the optimal target remains unknown.
Daniel Aletaha +7 more
doaj +4 more sources
The role of timely rheumatoid arthritis treatment effectiveness control
Consilium Medicum, 2023 Background. Regular assessment of rheumatoid arthritis (RA) activity is a key factor in therapy effectiveness improving. Aim. To prove that timely RA treatment control recommended by modern guidelines improves outcomes and reduce disability in real ...
Larisa M. Musaeva +3 more
doaj +1 more source
PLoS ONE, 2022 Introduction Rheumatoid arthritis (RA) composite disease activity indices have become handy tools in daily clinical practice and crucial in defining remission or low disease activity, the main target of the RA treatment.
Isabela Araújo Santos +24 more
doaj +2 more sources
Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity [PDF]
The Korean Journal of Internal Medicine, 2020 Background/Aims The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA ...
Kichul Shin +23 more
doaj +1 more source
Scientific Reports, 2022 Validity and risk of setting patient’s global assessment (PGA) ≤ 2 as a Boolean remission criteria substituting PGA ≤ 1 in treating rheumatoid arthritis (RA) was investigated.
Ichiro Yoshii +2 more
doaj +1 more source
Научно-практическая ревматология, 2019 Objective: to evaluate the clinical efficacy of the rituximab biosimilar Acellbia® at a dose of 600 mg intravenously at a 2-week interval in patients with active rheumatoid arthritis (RA) 12 and 24 weeks after initiation of treatment.Subjects and methods.
D. A. Kusevich +4 more
doaj +1 more source
Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis
Научно-практическая ревматология, 2012 Objective: to evaluate the impact of tocilizumab (TCZ) therapy on the level of acute-phase indicators, autoantibodies, and immunoglobulins (Ig) G, M, and A after 2, 4, 8, 12, and 24 weeks as compared to the clinical efficacy of TCZ using DAS 28, SDAI ...
Anastasia Sergeyevna Avdeyeva +5 more
doaj +1 more source
Correlation between neutrophil-to-lymphocyte ratio and disease activity score using SDAI in established rheumatoid arthritis patients [PDF]
Romanian Journal of RheumatologyRheumatoid arthritis (RA) is a multisystem inflammatory disorder predominantly affecting joint structures leading to joint erosions, destruction of cartilage and frank deformities if not treated.
Tabe Rasool +5 more
doaj +1 more source